Video

mRNA For Cancer Immunotherapy 2024 Outlook | Audience Q&A

In this segment, Andrew Case (Andy), Head of Supply Chain Cell and Gene Therapies, Genentech/Roche and Daniel Getts, CEO & Co-Founder, Myeloid Therapeutics answer audience questions regarding patient safety, foreseeable challenges in mRNA cancer immunotherapy for solid tumors, and much more.

access the Video!

Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Cell & Gene? Subscribe today.

Subscribe to Cell & Gene X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Cell & Gene

Please tell us more about you so that we can customize our newsletters to your specific interests:

Thermo Fisher Scientific Bioproduction